In a single-center, single-arm, open-label pilot study, 30 adults (mean age, 73.7 years) with GCA received 162 mg of tocilizumab as a subcutaneous injection once a week for 52 weeks, plus prednisone ...
Positive data was presented for Actemra (tocilizumab) therapy in patients with giant cell arteritis (GCA). WASHINGTON, DC — At the 2016 ACR/ARHP Annual Meeting, researchers from Genentech presented ...
A combination of tocilizumab plus prednisone-tapered therapy was superior to placebo plus steroid taper for achieving glucocorticoid-free remission in giant-cell arteritis (GCA), the phase 3 ...
"There is something new in giant cell arteritis at last, and the era of unending glucocorticoid treatment with no viable alternative is over," said John H. Stone, MD, PhD, of Harvard Medical School, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results